CDSCO Decoded · Issue 1 · November 2026
Every month we read the minutes of CDSCO’s Subject Expert Committees and pull out what matters for companies selling medicines in India: who was cleared to make and sell, whose biosimilar trial moved, and who was held back. Issue 1 covers the meetings held from 14 October to 12 November 2026.
Download this tracker as Excel
Cleared to make and sell
The committee recommended permission to manufacture and market these products. A recommendation goes to the Drugs Controller General of India for the final decision.
| Company | Product | Panel outcome | Meeting |
|---|---|---|---|
| CuraTeQ Biologics | Denosumab 60 mg/mL prefilled syringe and drug substance (biosimilar) | Recommended for manufacture and marketing | Analgesics, rheumatology and orthopaedics, 5 Nov |
| BioGenomics | Insulin glargine 100 IU/mL (biosimilar) | Recommended for manufacture and marketing | Endocrinology and metabolism, 4 Nov |
| MSN Laboratories | Apalutamide 240 mg tablet (new strength) | Recommended, with a Phase IV study condition | Oncology, 5 Nov |
| Akums Drugs | Eplerenone + torsemide tablets | Recommended after BE study review | Cardiovascular, 4 Nov |
| Windlas Biotech | Nebivolol + telmisartan + cilnidipine bilayer tablet | Recommended after Phase III review | Cardiovascular, 4 Nov |
Indian biosimilar and generic development
| Company | Product | Panel outcome | Meeting |
|---|---|---|---|
| Zydus Lifesciences | Pembrolizumab biosimilar ZRC 3323, Phase III against Keytruda | Changes to the trial design asked | Oncology, 28 Oct |
| Shilpa Biologicals | Pembrolizumab biosimilar | Protocol approved subject to changes | Oncology, 28 Oct |
| CuraTeQ Biologics | Bevacizumab biosimilar | Changes to the protocol asked | Oncology, 28 Oct |
| Enzene Biosciences | Cetuximab biosimilar | Clarifications and documents asked | Oncology, 28 Oct |
| Intas Pharmaceuticals | Golimumab biosimilar prefilled syringe, Phase 1/3 | Trial permitted with conditions | Analgesics, rheumatology and orthopaedics, 5 Nov |
| Mankind Pharma | Insulin degludec 100 units/mL, Phase I | Trial permitted as presented | Endocrinology and metabolism, 22 Oct |
| Alkem Laboratories | Insulin degludec 100 units/mL | Asked to validate degludec specific test kits | Endocrinology and metabolism, 4 Nov |
| Zydus Lifesciences | Capivasertib 160 mg and 200 mg tablets | BE study and Phase III permitted; BE report to be reviewed first | Oncology, 5 Nov |
Held back
| Company | Product | Panel outcome | Meeting |
|---|---|---|---|
| Sun Pharma | Semaglutide injection for additional indications | Phase III trial waiver not recommended | Endocrinology and metabolism, 4 Nov |
| Amneal Pharmaceuticals | Eliglustat sublingual film | More data asked | Endocrinology and metabolism, 4 Nov |
| Entod Pharmaceuticals | Losartan eye drops, 0.4 and 0.8 mg/mL, Phase II | Protocol changes asked: dosing that allows adequate sleep, and added dry eye tests | Ophthalmology, 14 Oct |
Vaccine trials
Indian vaccine makers dominated the two vaccine committee meetings, with four of six proposals sent back for protocol changes or cleared only on a revised design.
| Company | Product | Panel outcome | Meeting |
|---|---|---|---|
| Biological E | Liquid hexavalent vaccine (DTwP, hepatitis B, IPV, Hib), Phase III booster dose | Revised protocol asked, limited to the booster dose | Vaccines, 29 Oct |
| Indian Immunologicals | Hepatitis B vaccine (rDNA), Phase III | Revised protocol asked; sample size for lot to lot consistency found inadequate | Vaccines, 29 Oct |
| MSD Pharmaceuticals | Human papillomavirus 9 valent vaccine, recombinant | Study permitted as per the submitted protocol | Vaccines, 29 Oct |
| Syngene International | Mynflu001, recombinant adjuvanted influenza vaccine, Phase I | Phase I trial permitted on the revised protocol | Vaccines, 29 Oct |
| Serum Institute of India | Bivalent typhoid conjugate vaccine, Phase III | Revised protocol asked | Vaccines, 29 Oct |
| Human Biologicals Institute (Indian Immunologicals) | Live attenuated Zika vaccine, freeze dried, Phase I | Phase I trial permitted as presented | Vaccines, 12 Nov |
Innovator trials and label changes
| Company | Product | Panel outcome | Meeting |
|---|---|---|---|
| AstraZeneca | Saruparib, Phase III | Trial permitted | Oncology, 5 Nov |
| AstraZeneca | Laroprovstat with rosuvastatin, Phase III | Trial permitted | Cardiovascular, 4 Nov |
| AstraZeneca | AZD6234 | Trial permitted | Endocrinology and metabolism, 4 Nov |
| Novartis | Pacibekitug, Phase III | Trial permitted | Cardiovascular, 4 Nov |
| Novartis | FWY003, Phase I | Trial permitted with conditions, including heart checks before enrolment | Ophthalmology, 14 Oct |
| AbbVie | Venetoclax with acalabrutinib in untreated CLL | Label update recommended | Oncology, 5 Nov |
| Roche | Phesgo | Updated prescribing information approved | Oncology, 28 Oct |
What this means for market entry
- Pembrolizumab: count the Indian developers, not the patent date. See the patent expiry calendar.
- Insulins: degludec is the next biosimilar race, with Mankind and Alkem both in the trial pathway and glargine still drawing new entrants.
- Denosumab: a third Indian maker is close to market after Enzene and Zydus. See the drug market entry tracker.
Panel outcomes are summarised from the published SEC recommendations. A recommendation is not a final approval. Source: Market Research Outlook · Last reviewed: 17 Nov 2026 · How we verify
One email a month. Reply to any email to unsubscribe. Privacy policy
Frequently asked questions
What is a CDSCO Subject Expert Committee?
An expert panel that reviews new drug, biosimilar and trial applications and advises the Drugs Controller General of India, who takes the final decision.
How often is CDSCO Decoded published?
Monthly, after the committee minutes for the month are released.
Download this tracker as Excel
Every row on this page in one spreadsheet, ready to filter and share with your team. Free for internal use.
Your download is starting. Thank you.
We use your details only to share related MRO research. See our privacy policy.
Go deeper
Want a filing watched for you?
We track CDSCO panels for your molecule and competitors and tell you when a rival moves.